X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type C1 (NPC1).
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Product Name: Trappsol Cyclo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cyclo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 27, 2023
Details:
The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type C1 (NPC1).
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Product Name: Trappsol Cyclo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cyclo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger September 21, 2023
Details:
AMT-101 is a novel GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule, currently in development in Phase 2 clinical trials for chronic pouchitis and RA
Lead Product(s): AMT-101
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AMT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2023
Details:
AMT-126 is a novel GI-selective, oral fusion of IL-22 and AMT’s proprietary carrier molecule for diseases related to intestinal epithelial (IE) barrier defects.
Lead Product(s): AMT-101
Therapeutic Area: Gastroenterology Product Name: AMT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
AMT-101 is a novel GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule, currently in development in four Phase 2 clinical trials for chronic pouchitis, UC and RA.
Lead Product(s): AMT-101
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AMT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
AMT-101 is a novel GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule, currently in development in Phase 2 clinical trials for chronic pouchitis, UC and RA.
Lead Product(s): AMT-101
Therapeutic Area: Gastroenterology Product Name: AMT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
AMT-101 is a novel, GI-selective, investigational oral recombinant biologic fusion protein of human interleukin 10 (hIL-10), an anti-inflammatory cytokine, in development for the treatment of inflammatory bowel diseases and systemic inflammatory indications.
Lead Product(s): AMT-101,Adalimumab
Therapeutic Area: Gastroenterology Product Name: AMT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2022
Details:
AMT-101, a GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class profile in FILLMORE monotherapy trial .
Lead Product(s): AMT-101
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AMT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
AMT-101 is a novel, GI-selective, investigational oral recombinant biologic fusion protein of human interleukin 10 (hIL-10), an anti-inflammatory cytokine, in development for the treatment of inflammatory bowel diseases and systemic inflammatory indications.
Lead Product(s): AMT-101
Therapeutic Area: Gastroenterology Product Name: AMT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2021
Details:
AMT-101 (oral fusion protein of hIL-10 and AMT carrier) rapidly and efficiently transports through intestinal epithelia in healthy and inflamed conditions to target local intestinal tissue.
Lead Product(s): AMT-101
Therapeutic Area: Gastroenterology Product Name: AMT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
